Spatiotemporal sensitivity of embryonic heart specification to FGFR signaling in *Drosophila*

V. Yadav[1], N. Tolwinski[2,3] and T. E. Saunders[1,3,4,5,*]

[1] Mechanobiology Institute, National University of Singapore, Singapore

[2] Yale-NUS, National University of Singapore, Singapore

[3] Department of Biological Sciences, National University of Singapore, Singapore

[4] Institute of Molecular and Cell Biology, A*Star, Singapore

[5] Warwick Medical School, University of Warwick, Coventry, United Kingdom

* For correspondence: dbsste@nus.edu.sg

ABSTRACT

Development of the *Drosophila* embryonic mesoderm is controlled through both internal and external inputs to the mesoderm. One such factor is Heartless (Htl), a Fibroblast Growth Factor Receptor (FGFR) expressed in the mesoderm. Htl is involved in shaping the mesoderm at both early and later stages during embryogenesis. How Htl expression levels and timing of signaling affect mesoderm morphogenesis after spreading remains elusive. We have developed an optogenetic tool (Opto-htl) to control the activation of Htl signaling with precise spatiotemporal resolution *in vivo*. We find that the embryo is most sensitive to Htl over-activation within a developmental window of ~4 hours ranging from late stage 10 until early stage 13, which corresponds to early stages of heart morphogenesis. Opto-htl restores heart cells in *htl* mutants upon light activation, independent of its role in early mesoderm shaping events. We also successfully generated spatially distinct regions of Htl activity in the mesoderm using light-sheet microscopy. The developing tissue was unable to correct for the ensuing asymmetries in cell fate. Overall, Opto-htl is a powerful tool for studying spatiotemporal regulation of Htl signaling during embryogenesis.

INTRODUCTION

Morphogenetic events are tightly controlled in space and time (Wartlick *et al*., 2011; Ebisuya & Briscoe, 2018; Huang & Saunders, 2020). Throughout development, cells propagate,

migrate, and differentiate to form specialised structures in a highly regulated manner. Such self-organisation within the embryo is dictated by numerous signaling events, some of which are highly conserved across organisms (Wangler *et al.*, 2015; Beira & Paro, 2016; Li & Elowitz, 2019). Many of these signaling pathways interact with each other, generating complex network interactions and are interpreted differently by cells based on their competence to respond (Perrimon *et al.*, 2012; Sagner & Briscoe, 2017; Yin *et al.*, 2018; Li & Elowitz, 2019). These signaling networks are regulated in both space and time throughout morphogenesis to ensure that development is robust and reproducible (Amourda *et al.*, 2017; Huang *et al.*, 2017; Zinner *et al.*, 2020).

A crucial signaling pathway in regulating cell behaviour during development is the highly conserved Fibroblast Growth Factor Receptor (FGFR) pathway (Sopko & Perrimon, 2013). FGFRs are transmembrane proteins that belong to the receptor tyrosine kinase family. Ligand-binding leads to FGFR homo-dimerisation, initiating trans-phosphorylation events which ultimately activates transcription of several target genes (Fantl *et al.*,1993). This transcriptional response regulates different cellular responses, such as changes in cell morphology, proliferation, adhesion, migration and differentiation (Spivak-Kroizman *et al.*, 1994; Mohammadi *et al.*, 1996; Thisse & Thisse, 2005; Teven *et al.*, 2014; Mele & Johnson, 2020). Due to their involvement in key cellular processes, FGFRs when mutated can promote cancer development and progression (Turner & Grose, 2010; Wesche *et al.*, 2011; Presta *et al.*, 2017).

There are two known FGFRs in *Drosophila* that control distinct developmental processes, *heartless* (*htl*) and *breathless (btl)*. These bind three ligands in total - Pyramus, Thisbe and Branchless (Stathopoulos *et al.*, 2004; Kadam *et al.*, 2009). This compares with four known FGFRs and at least 22 associated ligands in humans that bind each other in several different combinations (Ornitz & Itoh, 2015). The small number of receptor-ligand combinations makes *Drosophila* an excellent system to explore the basic interactions underlying FGFR action. In *Drosophila, htl* expression is important for proper development of several mesoderm derived tissues, including the heart and muscles (Beiman *et al.*, 1996; Gisselbrecht *et al.*, 1996; Shishido *et al.*, 1997). *btl* expression is required for proper morphogenesis of the trachea (Klambt *et al.*, 1992; Reichman-Fried *et al.*, 1995). Both Htl and Btl are essential in driving proper migration of mesodermal, glial, and tracheal cells (Muha & Müller., 2013). For instance, Htl plays a role in the spreading of the mesoderm over the ectoderm to form a monolayer during

early stages of embryogenesis (Wilson *et al*., 2004; Wilson *et al*., 2005; McMahon *et al*., 2010;

Bae *et al*., 2012). Uniform spreading of the mesoderm is crucial for proper cell-fate

specification of different cell types within the mesoderm at later stages (Stathopoulos *et al*.,

2004; Kadam *et al*., 2009). In *htl* mutants, mesoderm cells fail to undergo proper spreading and

form irregular and multilayer arrangements. This lack of structure prevents mesodermal cells

from receiving precise spatial cues from the ectoderm. Later in development, Htl is also

involved in the specification of different cell types derived from the mesoderm (Michelson *et*

al., 1998). *htl* null mutants lack precursors of pericardial and heart cells, have defects in visceral

mesoderm, and show reduced, irregular muscle patterns (Beiman *et al*., 1996; Stathopoulos *et*

al., 2004; Kadam *et al*., 2009).

The role of FGFR in cell fate specification has been extensively studied (Carmena *et al*., 1998;

Ciruna & Rossant., 2001; Mandal *et al*., 2004). While previous work has provided detailed

insights into how Htl controls the movement of mesodermal cells during the spreading phase

(McMahon *et al*., 2008), the *in vivo* dynamics of Htl action within the developing mesoderm

remain elusive after the initial stages of spreading. Genetic perturbations of *htl* offer only a

limited exploration of the spatiotemporal range of Htl activity. In recent years, the use of

optogenetics to tune signaling pathway responses has become a powerful tool *in vivo* (Huang

et al., 2017; Kaur *et al*., 2017; Viswanathan *et al*., 2019; Johnson *et al*.,2020). Optogenetic

approaches enable precise spatiotemporal tuning of target activity, enabling *in vivo* signaling

dynamics to be dissected.

Here, we utilised an optogenetic tool (termed Opto-htl) to activate Htl signaling in a

spatiotemporally controlled manner during *Drosophila* embryo development. Upon

illumination with 488nm light, Opto-htl functions as a constitutively active receptor, capable

of activating downstream factors of the FGFR pathway, such as the extracellular signal

regulated kinase (Erk). Opto-htl restored a significant number of heart cells within a *htl* mutant

upon light activation, though it did not fully rescue the mutant phenotype. Constitutive

activation in the mesoderm of the wild-type led to several developmental defects, the severity

of which varied with changes in light intensity, timing, and spatial organisation of the light

exposure. We identified a time window of sensitivity to FGFR over-activation (stage 10 till

late stage 12 of embryogenesis), illumination during which was both necessary and sufficient

to induce the phenotypic defects. Together, these results demonstrate sensitivity of the Htl-

dependent processes (particularly heart formation) to over-activation of Htl.

RESULTS

Opto-htl can stimulate FGFR activity

To generate an *in vivo* optogenetic tool for FGFR activation, we utilised Cryptochrome2

(CRY2), a light-interacting molecule that undergoes dimerisation upon exposure to 488nm blue

light (Yu *et al*., 2009). The cytoplasmic domain of *htl* was fused with CRY2-mCherry and the

resulting fusion protein (termed Opto-htl) was anchored to the membrane by a myristoylation

(myr) signal sequence (Kim *et al*., 2014). Light exposure induces dimerisation of CRY2,

bringing two receptor molecules together and triggering a phosphorylation cascade, which

should lead to ligand-independent activation of target genes downstream of the receptor (Fig.

1A).

We used Twi-Gal4 to drive Opto-htl (Twi-Gal4>UAS-htl-CRY2-mCherry) (Fig. 1B, top) in

the mesoderm. We validated that our construct was expressed in the mesoderm and mesoderm-

derived tissues at different stages throughout embryogenesis (Fig. 1B). Live imaging showed

that expression levels remained low until stage 10 but subsequently increased and were

maintained in the mesoderm throughout embryogenesis (Movie S1). Twi-Gal4>Opto-htl

embryos maintained in the dark throughout embryogenesis hatched with similar frequency to

wild-type (OreR) embryos (Movie S3). However, upon constant light exposure (Methods) from

stage 5 onwards, there was a significant drop in hatchability and 97% of embryos died before

hatching (Fig. 1C). These embryos developed up until the later stages of embryogenesis before

dying unhatched (Movie S3).

Next, we tested the constitutive activation of the FGFR pathway via Opto-htl. We used the

phosphorylation of Erk as a readout for the MAPK/Erk pathway downstream of FGFR (Gabay

et al., 1997). Erk activation to doubly phosphorylated Erk (dpErk) leads to transcription of

several target genes that regulate growth and proliferation (Lavoie *et al*., 2020). We tested for

differences in the levels of dpErk in Opto-htl embryos kept under dark and light conditions.

We illuminated Twi-Gal4>Opto-htl embryos up until the end of germ band elongation (late

stage 10 / early stage 11), then fixed and stained them with anti-dpErk antibody alongside embryos kept in the dark. We observed an increase in dpErk levels in embryos exposed to light as compared to the ones fixed and stained at a similar stage in the dark (Fig. 1D). We also tested Erk activation in the hindgut epithelium (ectoderm-derived) which does not express high levels of dpErk in wild-type conditions. We used Byn-Gal4 to express Opto-htl in the hindgut epithelium and again tested for dpErk levels under dark and light conditions (Fig. 1E). Comparing the dpErk intensity for dark and light conditions in both tissues, dpErk levels were significantly increased upon light activation (Fig. 1F-G). We conclude that Opto-htl can be used to induce Erk activation *in vivo* upon illumination.

Opto-htl can induce heart cells in a *heartless* mutant

To further test the functionality of Opto-htl, we expressed it against a null *htl* mutant background to explore the extent of rescue of phenotypes at different stages upon light illumination. Homozygous mutants for *htl* undergo improper spreading of mesoderm cells at stage 10 forming irregular and multilayer arrangements (Stathopoulos *et al*., 2004), lack pericardial precursors, a proper muscle structure, pattern and, as the name suggests, fail to form a proper heart (Beiman *et al*., 1996) (Fig. 2A). A previous tool to induce *htl* over-expression, htl-λ (Michelson *et al*., 1998; Wilson *et al*., 2005), was able to partially rescue the *htl* mutant, with some Eve-positive cells (precursors for pericardial and dorsal muscles) in the mesoderm restored.

We tested for rescue of heart cells at stage 16 in homozygous *htl* mutants expressing Twi-Gal4>Opto-htl with and without light activation. Tinman (Tin) is a transcription factor required for the specification of all heart cells and a subset of muscles (Bodmer, 1993). At stage 15/16, Tin is expressed in a major portion of the cardioblasts and pericardial cells (Alvarez et al., 2003). We found that homozygous embryos maintained in light showed restoration of Tin-positive heart cells at stage 16 when compared to embryos kept in the dark (Fig. 2B-C). In comparison, in wild-type embryos, there are around 104–Tin-positive cells in hemisegments A2-A8 (52 cardioblasts and pericardial cells each) at late stage 15/16 (Alvarez et al., 2003). Although Tin-positive cells were greatly increased under light activation of Opto-htl in *htl* null embryos, there was substantial variation in their spatial arrangement between embryos. The Tin-positive cells were located near the embryonic midline, but they failed to form a coherent

heart structure. This is likely a consequence of embryos failing to undergo uniform mesoderm spreading over the ectoderm early on.

Opto-htl showed no rescue of phenotypes during early stages of development (Fig. S1). Since Opto-htl expression levels are generally low during early stages (Movie S1), it is possible that rescue during this stage requires higher levels of FGFR signaling than we currently achieve. These results are consistent with previous findings that Htl-dependent cell fate decisions in the mesoderm after stage 10 are decoupled from its role in mesoderm spreading (Michelson *et al.*, 1998), though formation of robust organs requires synergy between both processes.

Activation of Opto-htl induces ectopic Tin-positive cardioblasts

Light activation of Opto-htl in the wild type mesoderm interfered with embryonic development, leading to a significant increase in lethality. We focused on the effect of Opto-htl activation on the development of mesoderm-derived tissues, particularly the heart. The heart in wild-type and Opto-htl embryos kept under dark is composed of two rows of cells (Fig. 3A left) with a repeated pattern of four Tin-positive and two-Seven-up (Svp) positive cells (Ahmad, 2017; Vogler & Bodmer, 2015) (Fig. 3B, top). The cells comprising these two rows are specified on both lateral sides of the embryo by the end of stage 12 after which they start migrating towards each other and match in a highly precise fashion (Reim & Frasch., 2010, Zhang *et al.*, 2018; Zhang *et al.*, 2020) (Fig. 3B top, Movie S4). Upon illumination, the stage 16 heart in Twi-Gal4>Opto-htl embryos showed a significant increase in the number of cardioblasts (Fig. 3A right and Fig. 3B bottom). There was an increase in the number of cardioblasts per hemisegment, but with substantial variation between embryos (Table 1). The clusters still had Svp-positive cells appearing in doublets, identifiable by reduced Fasciclin-III (Fas3) expression and morphology (Zhang *et al.*, 2018) (asterisk in Fig. 3B) as in wild-type embryos, but they no longer matched with their contralateral partners. In some cases, the heart structure even becomes discontinuous (Movie S5). The observed asymmetries in the light-activated Opto-htl embryos suggested that the ectopic heart cells were generated asymmetrically between the contralateral sides of the embryos. Some embryos even developed multiple branches emanating from what appeared to be the primary heart vessel (arrowhead Fig. 3B).

Activation of Opto-htl disrupts mesoderm-derived muscle formation

In wild-type embryos, the dorsal muscles - DA1 muscles - are initially flower like structures formed from a cluster of Eve-positive cells around both sides of the heart (Han & Bodmer., 2003; Schwarz *et al*., 2018). Upon staining with Eve antibody, we observed that the DA1 muscle precursors are completely missing from Opto-htl embryos kept under light (Fig. 3C, Eve). These embryos also showed a reduced number of muscle-forming Mef2 positive cells (Fig. 3C, brackets) (Mef-2 is a key transcription factor that marks and directs proper specification of the heart and muscle cell types (Bour *et al*., 1995; Lilly *et al*., 1995)). We next visualised the muscle patterns at stage 16 using the mCherry signal marking Opto-htl. In wild-type embryos and in Opto-htl embryos kept in dark, the somatic muscles were arranged and attached to the body wall in regular patterns (Zhou *et al*., 2019) (Fig. 3D). This pattern was disrupted in Opto-htl embryos kept under light, with the muscles appearing diffused and disrupted (Fig. 3D). Overall, we see that over-activation of Opto-htl leads to a loss of structural organisation within mesoderm-derived tissues.

Opto-htl allows spatially precise activation of Htl signaling within the developing mesoderm

We used a light-sheet microscope to generate a spatially restricted region of Opto-htl activation within a developing embryo. Since the light-sheet illuminates and collects the signal from a single optical section at a time, we are able to partition a given embryo into illuminated and non-illuminated sections. (Kaur *et al*., 2017). A Twi-Gal4>hand::GFP; Opto-htl embryo was mounted such that the illumination plane was parallel to the long-axis of the embryo. To generate spatially heterogeneous activation of Opto-htl, we scanned the Opto-htl embryos with the 488nm laser to a depth of ~35um from the embryo surface on one lateral side, so as to illuminate the heart precursors on only one side of the embryo (Fig. 4A). At stage 16, we imaged the embryo from the dorsal side to image the heart and compared Hand::GFP signals from the illuminated and non-illuminated sides. We observe a striking difference between the number of heart cells on both sides, with the non-illuminated side resembling the dark condition phenotype while the illuminated side showed multiple ectopic cardioblasts (Fig. 4B, asterisk).

We observed ectopic cardioblasts in the illuminated side immediately after the end of illumination at stage 13 (Fig. 4C, left). By the end of stage 15 (Fig. 4C, right), the non-illuminated side resembled the wild type embryo in its arrangement and number of heart cells while the illuminated side had substantial ectopic cardioblasts arranged irregularly along the embryonic midline. These results suggest that the two lateral sides of the mesoderm develop independently from each other, and they cannot correct for defects in the formation of their contralateral partner which is consistent with the fact that the mesodermal cells do not mix extensively along the lateromedial axis and their spatial information with respect to one another is more or less conserved (Ortega & Hartenstein, 1985).

Severity of Opto-htl induced phenotypes is dosage dependent

We observed the aforementioned phenotypic defects in Opto-htl embryos upon continuous and uniform illumination at a fixed intensity of 1mW (measured at the sample plane). Next, we varied the dosage of signaling via Opto-htl by illuminating Opto-htl embryos with different light intensities using a Nikon LED light base as the light source. We used light intensities at 2 mW, 1 mW, 0.25 mW, 0.1 mW, and 0.01 mW (measured using an intensity power meter set at the 488nm range) for illuminating Twi-Gal4>hand::GFP; Opto-htl embryos from stage 5 up until stage 15/16 and then imaged the heart in each embryo. Hand::GFP is expressed at stage 16 in all the heart cells and the adjacent visceral mesoderm. In Fig. 5A we depict the most and least defective heart images at each intensity, based on the number of ectopic cardioblasts. At low intensities (0.01mW), the least defective embryos closely resembled embryos maintained in the dark condition (Fig. 5B), with only a few ectopic cardioblasts. At 0.1mW, ectopic cardioblasts were more apparent in some embryos, though the overall structure still resembled the non-illuminated embryos. For intensities 0.25mW and above, the heart defects were marked, with major structural changes to the heart vessel (branching, inconsistent matching).

After imaging the embryos at stage 16, we let them develop further and scored their hatchability. We found that increased intensity led to lower survival rates. At 0.1mW exposure, we observe a survival rate of around 57% as compared to a 100% lethality observed at intensity values of 1mW or higher (Fig. 5C). Despite significant ectopic cardioblasts, 52% of the embryos illuminated at 0.25mW still managed to hatch, possibly due to reduced severity of some other defects at lower intensities.

We compared these results with the other constitutively active form, htl-λ (Michelson *et al*.,

1998; Wilson *et al*., 2005). htl-λ did not induce lethal phenotypic defects when expressed in

the mesoderm. Tin and Eve patterns at stage 15 in Twi-Gal4>htl-λ embryos showed only small

phenotypic variation from wild-type patterns (Fig. S3). The heart phenotype observed for htl-

λ resembled that of Opto-htl embryos at lower intensity illuminations (<0.1mW). Of course,

differences between the scales of action for the two constructs cannot be ruled out. At higher

light activation, we see stronger phenotypes in the Opto-htl embryos as compared to htl-λ. Our

results suggest that specification of the cardiac vessel within the mesoderm is highly sensitive

to FGFR activity levels.

Embryo development is sensitive to Opto-htl activation only during stages 10-12

In the early embryo, Htl plays an important role in regulating mesoderm spreading (Wilson *et*

al., 2005; McMahon *et al*., 2010), but the dynamics of its activity later in development are less

well known. We used Opto-htl to activate Htl signaling during distinct developmental time

windows to disentangle its early and later effects on embryo development and to test when the

developing mesoderm is most sensitive to Htl over-activation.

We illuminated Twi-Gal4>Opto-htl embryos during three separate time windows (Fig. 6A): (i)

from stage 5 to stage 10 (~2.5 hours), during which the presumptive mesoderm forms the

ventral furrow and undergoes spreading over the ectoderm to form a monolayer; (ii) from late

stage 10 to late stage 12 (~4 hours), during which the specification of the presumptive

mesoderm into different cell types occur; and (iii) from stage 13 up to stage 16 (~4 hours),

during which cardioblasts migrate to the embryo midline and form the heart. We observe that

nearly all embryos illuminated during windows (i) and (iii) hatch. However, almost all embryos

illuminated between stages 10 and 12 fail to hatch (Fig. 6A). As previously stated, Opto-htl

levels at early stages i.e. during time window (i), can only be detected by anti-mCherry

antibody staining, suggesting low expression levels (Movie S1).

We next performed illuminations during more fine-tuned developmental windows (Fig. 6B-C,

Table 2A-B). We see a sharp transition in survivability around stage 12 where embryos

illuminated prior to stage 12 show high lethality, and embryos illuminated only after stage 12

show high survivability (Fig. 6B). Performing the opposite light illumination protocol, embryos illuminated until stage 10 but then kept in the dark all hatched. Embryos illuminated until stage 11 had a survivability of around 50%. Developmental processes around stage 11-12 appear to be especially sensitive to Opto-htl activation. The specification of different cardiac progenitors occurs during this stage (Reim & Frasch., 2010). To determine what defects were induced by illumination of Opto-htl during time window (ii), we let embryos illuminated during this window continue to develop in the dark from stage 13 onwards and fixed them at stage 16. We observed that these embryos had ectopic Mef-2 positive cardioblasts (Fig. 6D, arrows), similar to Opto-htl embryos illuminated throughout development. Further, the Mef-2 positive muscle cells were also reduced as seen in the body wall muscles (Fig. 6D , brackets).

We observed that activation of Opto-htl during the developmental period from late stage 10 until late stage 12 was both necessary and sufficient to induce the described mesodermal defects. This window is crucial for heart morphogenesis and requires precise levels of FGFR activation to ensure proper cell fate specification and robust development (Reim & Frasch, 2010). In contrast, later developmental processes (post stage 13) appear to be able to tolerate a much higher range of Htl activity, possibly because cell-fate specification has already happened by this time and/or cells can buffer any increased Htl activity.

DISCUSSION

The embryonic mesoderm gives rise to a diverse range of cell types that form the heart, visceral musculature, haemocytes and the fat body. Htl plays a crucial role in shaping the mesoderm by ensuring (i) uniform spreading of the mesoderm over the ectoderm and (ii) subsequent fate specification of different tissue precursors (Michelson *et al.*, 1998; Wilson *et al.*,2000; Stathopoulos *et al.*, 2004; Kadam *et al.*, 2009). Here, we have demonstrated the use of an optogenetic tool (Opto-htl) to study spatiotemporal regulation of Htl signaling by controlling its level of activation *in vivo* along with precisely defined spatial and temporal windows. We found that the embryo is highly sensitive to Htl over-activation during the time window from late stage 10 till end of stage 12 (early stages of heart morphogenesis). Illumination from stage 13 onwards did not result in any remarkable defects (Fig. 6). Within the stage 10 to 12 window, the severity of the phenotype decreased with decreasing light intensity (Fig. 5A). Opto-htl provides a distinct advantage over previous studies of Htl over-activation, as it allows careful

tuning of the strength of the pathway response. We can induce a stronger signaling dosage response in the mesoderm from stage 10 by increasing the light intensity of illumination.

There was no apparent increase in the total number of mesodermal cells upon light activation in Twi-Gal4>Opto-htl embryos observed at stage 11(Fig. S2). By stage 13, however, we see an increase in the number of Hand::GFP-positive cells in these embryos when exposed to light (Movie S5B-C and Fig. 4C, compare the non-illuminated and illuminated sides). We currently do not have a live reporter for cardioblasts with clear expression at stage 10-12 (Hand::GFP comes up in stage 13). In related work, we are developing new lines to explore the dynamics of early heart formation. We can then unravel whether the changes in cell number are related to over-proliferation of Tin-positive cardioblasts or switches in cell identity of other mesodermal cells and also decipher the exact timing of these events during development.

Surprisingly, illuminated Twi-Gal4>Opto-htl embryos at 1mW intensity do not show an increase in number of Eve-positive precursors (at stage 11) that form future pericardial cells and DA1 muscles. This contrasts with the htl−λ construct, that induced additional Eve-positive precursors at stage 11 but did not result in a lethal phenotype at later stages (Fig. S3). In Twi-Gal4>Opto-htl embryos, Eve-positive DA1 muscles at stage 16 are completely missing from light-activated (1mW) embryos at stage 16 (Fig. 3C). At low light activation, our Opto-htl phenotype was similar to that of htl-λ with respect to the number of ectopic Tin-positive heart cells observed at stage 16 (Fig. S3, asterisk). It is possible that at higher light intensity of 1mW, Opto-htl over-activation of the FGFR pathway is inducing conversion from a muscle cell fate to a cardiac or pericardial cell fate; *i.e.* Mef-2 positive muscle founders adopting a Tin-positive cardioblast fate and Eve-positive dorsal muscle cells adopting a pericardial fate. Therefore, Opto-htl potentially enables fine-tuning of FGFR-dependent cell fate decisions within the developing mesoderm. This opens up the possibility to explore the role of *htl* activity in controlling mesoderm cell behaviour with greater precision and across a greater range than possible with other tools.

There are several different pathways downstream of Htl (Ras/Raf/MAPK, PLCγ, PI3/AKT) characterised based on their molecular components and the response they generate (Ornitz & Itoh., 2015). Each pathway activates transcription of a set of different genes generating cellular responses such as proliferation, differentiation, migration, cell survival, and apoptosis. The

MAPK pathway activation plays an important role in development of several different cancer types (Roskoski., 2019). We compared the developmental effect of constitutive activation at the receptor level with Opto-htl (potentially activating all downstream pathways) to activation of only the Ras/Raf/MAPK pathway in the mesoderm by driving Opto-SOS (Johnson *et al*., 2017) with Twi-Gal4. Upon illumination, we observe similar phenotypes in the heart as with Opto-htl; abundance of Tin-positive cardioblasts and loss of DA1 muscles (Fig. S4). The phenotypes are pronounced at 4.5mW illumination intensity, at which no DA1 muscles are observed and there is an abundance of Eve-positive pericardial cells and Tin-positive cardioblasts. At lower intensities, some of the DA1 structure is maintained. Hyperactivation of the Ras/Raf/MAPK pathway alone leads to phenotypes similar to Opto-htl in the mesoderm. This suggests that MAPK signalling dosage is critical in regulating cell proliferation and cell fate specification events in the mesoderm during stages 10-12.

We observed that Opto-htl can restore Tin-positive cardioblasts in *htl* null mutants upon light activation (Fig. 2C). Specification of Tin-positive heart precursors relies on the dorsal-most mesodermal cells receiving cues from Decapentaplegic and Wingless (Reim & Frasch., 2010), which emanate from the neighbouring ectodermal tissue. In *htl*-null mutants, mesoderm spreading is defective, but some cells still lie near to the neighbouring ectoderm. This likely explains how Opto-Htl is able to activate *tin* expression in *htl* null mutants and why the resulting pattern of Tin-positive cardioblasts is heterogeneous. This is consistent with the role of Htl in heart cell specification, independent from its role in mesoderm spreading (Michelson *et al*, 1998).

Our results suggest that Htl-dependent cell fate decisions are highly stage specific and dosage dependent. An increase in dosage leads to variations in different cell types of the heart and muscle lineage. These events are specifically restricted to a time window for Htl over-activation between late stage 10 and early stage 13, though recall that the lower time bound is uncertain due to relatively lower expression levels of Twi-Gal4>Opto-htl at early stages. Using Opto-htl to control several parameters of FGFR activation - dosage, spatial region of activation, and timing of activation - we have provided insight into different modes of Htl action in the developing mesoderm. In future work, we aim to fine tune these parameters further, to study how they affect cell fate changes *in htl* null embryos.

FGFR signalling plays a crucial role in the development and maintenance of several different
organ systems in humans (heart, lungs, brain, skeletal muscles, etc.) and is also a target in
disease therapies (Xie *et al.,* 2020). There is evidence from animal studies that FGFR signal
activation has potential for use in tissue regeneration and repair (Engel *et al*., 2006; Korf-
Klingebiel *et al*., 2011; House *et al*., 2015). Optogenetic control over signalling pathways
allows us to fine tune their activation or deletion in a highly controlled spatiotemporal manner.
Studying the conditional effects of these manipulations on development and disease
pathogenesis has the potential to lead to novel therapeutics.

Acknowledgements:

We thank Kenji Matsuno, Maria Leptin and Zhe Han for fly lines. We thank Manfred Frasch,
James Sharpe and Eileen Furlong for the Tinman, Eve and Mef-2 antibodies respectively. We
acknowledge members of the Saunders laboratory for fruitful discussions. This work was
supported by a Singapore Ministry of Education AcRF Tier 3 Grant (MOE2016-T3-1-002).

Author Contributions:

All authors designed and planned the study. VY performed all experiments and data analysis,
with guidance from NT and TES. VY and TES wrote the initial manuscript, with all authors
contributing to the final manuscript.

Materials and Methods:

Fly stocks, husbandry and genetics

UAS-htl-Cry2mCherry construct was generated using Gibson assembly (NEB) of four fragments: pPW vector backbone digested and purified, synthesized src42A myristoylation (myr) signal sequence, PCR amplified cytoplasmic region of htl/btl from cDNA, PCR amplified CRY2mCherry sequence from the AddGene plasmid #26866 (Kennedy *et al.*, 2010). The recombinant plasmid was sent to BestGene Inc for P-element transformation. Twi-Gal4 (BDSC58804, BDSC2517) was used to drive expression in the mesoderm and Byn-Gal4>UAS-myr-GFP was used to drive expression in the hindgut (kindly provided by Kenji Matsuno). To mark the heart cells for live imaging, we used Hand::GFP (GFP driven by the Hand cardiac and hematopoietic (HCH) enhancer (Han, 2006)) and formed a stable line: Hand::GFP;UAS-htl-Cry2mCherry.

For the rescue experiments, UAS-htl-Cry2mCherry on 2nd chromosome was combined with the htl^{AB42} null mutant on 3rd chromosome (BDSC 5370). Similarly, Twi-Gal4 on 2nd chromosome (BDSC2517) was combined with htl^{AB42} null mutant to form a stable line. UAS-htl-Cry2mCherry; htl^{AB42} / TM3-ftz-lacz virgin females were crossed to Twi-Gal4; htl^{AB42} / TM3-ftz males resulting in 25% homozygous mutant embryos expressing Twi-Gal4>UAS-htl-Cry2mCherry. All fly lines were raised at 25°C.

Identification of homozygous *htl* mutant embryos for rescue experiments

For the rescue crosses, a balancer chromosome carrying a lacZ-transgene was used. lacZ expression was driven by the ftz-promoter and was detected in embryos using anti- β-Gal antibody (DSHB 40-1a). For cross-section staining, lacZ-positive and lacZ-negative embryos were sorted under a dissecting microscope based on the β-gal staining pattern prior to cutting in 70% glycerol using a 25-gauge needle.

Immunostaining

Embryos were collected at the desired stages, then dechorionated using bleach and fixed in heptane saturated with 37% paraformaldehyde (PFA) for 50 minutes. The vitelline membrane was subsequently removed using a needle. Prior to immunostaining, the embryos were blocked in 10% BSA-PBS. Antibodies used were mouse anti- β-Gal (1:100, DSHB), rabbit anti-

mCherry (1:100, Abcam), guinea pig anti-Eve (1:800, kindly provided by James Sharpe), rabbit

anti-dpERK (1:100, CST), mouse anti-fas3 (1:300, DSHB), Rabbit anti-tin (1:1000, kindly

provided by Manfred Frasch), mouse anti-myosin heavy chain (1:100, DSHB), rabbit anti-

mef2 (1:800, kindly provided by Eileen Furlong). Primary antibodies were detected with Alexa

Fluor-labelled secondary antibodies (1:500; LifeTech). Embryos were mounted in AquaMount

(PolySciences, Inc.) and imaged using a Zeiss LSM710 microscope with a C-Apochromat 40x

water-immersion objective or a Nikon A1-RS scanning confocal microscope with 40x water-

immersion objective. For dpERK intensity comparisons, both dark and light condition embryos

were collected, stained and imaged under same conditions (antibody dilutions, laser power,

etc).

Illumination experiments

To score hatchability, embryos were imaged on a bright-field stereomicroscope at 25°C. To

maintain the dark condition where needed, embryos were observed with the light source

covered with amber paper to block 488nm light. For illuminating embryos, we used a Nikon

LED light base as the light source and measured different light intensities using an intensity

power meter set at the 488nm range. All experiments were carried out at 1 mW (measured at

the sample plane) unless otherwise stated. For different time-window illuminations, stage 5

embryos were collected in the dark condition (488nm light blocked by amber paper) and then

exposed to light. For keeping embryos in dark for recovery after illumination, we used a box

covered with aluminium foil. For staining experiments, dark and light condition embryos were

fixed and stained simultaneously at exactly similar stages. All embryos were collected and

staged according to Ortega & Hartenstein (1985).

Light-sheet microscopy for spatially controlled activation

Embryos were dechorionated using bleach, mounted into a capillary containing 1% low-

melting agarose (Sigma) in an upright position and imaged on a Z.1 light-sheet fluorescence

microscope (Carl Zeiss, Germany) using a 40x water immersion objective. The light-sheet

microscope was equipped with 30 mW 488 nm and 20 mW 561 nm lasers with BP505–545

and LP585 emission filters respectively. Embryos were imaged using dual-side illumination

by a light-sheet modulated into a pivot scan mode. The 488 nm excitation laser was used at 6%

power with 7.5ms exposure time and the 561 nm excitation laser was used at 13% laser power

with 20ms exposure time. For control embryos, only the 561 nm laser was used for scanning.

For spatial control of activation, embryos were mounted vertically and scanned with the 488nm

laser from the lateral side such that the light-sheet was parallel to the plane of the embryo.

~35um of slices from the embryo surface were scanned so as to illuminate the heart precursors

on only one side of the embryo. We scanned embryos with the 488nm laser from stage 10 till

stage 13 and then we let embryos develop in the dark until stage 16 (no scanning with 488nm

laser). At stage 16, we scanned the dorsal side of the embryos to image the heart and compared

signals from the illuminated and non-illuminated sides.

References

Ahmad, S. M. (2017). Conserved signaling mechanisms in Drosophila heart development.

Developmental Dynamics, *246*, 641–656.

Alvarez, A. D., Shi, W., Wilson, B. A., & Skeath, J. B. (2003). pannier and pointedP2 act

sequentially to regulate Drosophila heart development. Development, 130, 3015-3026.

Amourda, C., & Saunders, T. E. (2017). Gene expression boundary scaling and organ size

regulation in the Drosophila embryo. *Development, growth & differentiation*, 59, 21-32.

Bae, Y. K., Trisnadi, N., Kadam, S., & Stathopoulos, A. (2012). The role of FGF signaling in

guiding coordinate movement of cell groups. Guidance cue and cell adhesion regulator? *Cell*

Adhesion and Migration, *6*, 397–403.

Beiman, M., Shilo, B. Z., & Volk, T. (1996). Heartless, a Drosophila FGF receptor homolog,

is essential for cell migration and establishment of several mesodermal lineages. *Genes and*

Development, *10*, 2993–3002.

Beira, J. V., & Paro, R. (2016). The legacy of Drosophila imaginal discs. *Chromosoma*, 125,

573-592.

Bodmer, R. (1993). The gene tinman is required for specification of the heart and visceral

muscles in Drosophila. *Development*, *118*, 719–729.

Bour, B. A., O'Brien, M. A., Lockwood, W. L., Goldstein, E. S., Bodmer, R., Taghert, P. H.,
& Nguyen, H. T. (1995). Drosophila MEF2, a transcription factor that is essential for
myogenesis. *Genes & development*, *9*, 730-741.
520
521 Bryantsev, A. L., & Cripps, R. M. (2009). Cardiac gene regulatory networks in Drosophila.
522 *Biochimica et Biophysica Acta (BBA)-Gene Regulatory Mechanisms*, 1789, 343-353.
523
524 Campos-Ortega, J. A., & Hartenstein, V. (1985). The embryonic development of Drosophila
525 melanogaster. Berlin/Heidelberg: Springer-Verlag.
526
527 Carmena, A., Gisselbrecht, S., Harrison, J., Jiménez, F., & Michelson, A. M. (1998).
528 Combinatorial signaling codes for the progressive determination of cell fates in the Drosophila
529 embryonic mesoderm. *Genes and Development*, *12*, 3910–3922.
530
531 Ciruna, B., & Rossant, J. (2001). FGF signaling regulates mesoderm cell fate specification and
532 morphogenetic movement at the primitive streak. *Developmental cell*, 1, 37-49.
533
534 Ebisuya, M., & Briscoe, J. (2018). What does time mean in development? *Development*, 145,
535 dev164368.
536
537 Engel, F. B., Hsieh, P. C., Lee, R. T., & Keating, M. T. (2006). FGF1/p38 MAP kinase inhibitor
538 therapy induces cardiomyocyte mitosis, reduces scarring, and rescues function after myocardial
539 infarction. Proceedings of the National Academy of Sciences, 103, 15546-15551.
540
541 Fantl, W. J., Johnson, D. E., & Williams, L. T. (1993). Signaling by receptor tyrosine kinases.
542 *Annual review of biochemistry,* 62, 453-481.
543
544 Gabay, L., Seger, R., & Shilo, B. Z. (1997). MAP kinase in situ activation atlas during
545 Drosophila embryogenesis. *Development*, *124*, 3535-3541.
546
547 Gajewski, K., Kim, Y., Lee, Y. M., Olson, E. N., & Schulz, R. A. (1997). D-mef2 is a target
548 for Tinman activation during Drosophila heart development. *EMBO Journal*, *16*, 515–522.
549

Gisselbrecht, S., Skeath, J. B., Doe, C. Q., & Michelson, A. M. (1996). heartless encodes a

fibroblast growth factor receptor (DFR1/DFGF-R2) involved in the directional migration of

early mesodermal cells in the Drosophila embryo. *Genes and Development*, *10*, 3003–3017.

Han, Z., & Bodmer, R. (2003). Myogenic cells fates are antagonized by Notch only in

asymmetric lineages of the Drosophila heart, with or without cell division. *Development*, *130*,

3039-3051.

Ho, J., Tumkaya, T., Aryal, S., Choi, H., & Claridge-Chang, A. (2019). Moving beyond P

values: Everyday data analysis with estimation plots. *Nature Methods*, 16, 565-566.

House, S. L., Wang, J., Castro, A. M., Weinheimer, C., Kovacs, A., & Ornitz, D. M. (2015).

Fibroblast growth factor 2 is an essential cardioprotective factor in a closed-chest model of

cardiac ischemia-reperfusion injury. Physiological reports, 3, e12278.

Huang, A., Amourda, C., Zhang, S., Tolwinski, N. S., & Saunders, T. E. (2017). Decoding

temporal interpretation of the morphogen Bicoid in the early drosophila embryo. *ELife*, *6*, 1–

21.

Huang, A., & Saunders, T. E. (2020). A matter of time: Formation and interpretation of the

Bicoid morphogen gradient. *Current Topics in Developmental Biology, 137, 79-117*

Johnson, H. E., Djabrayan, N. J., Shvartsman, S. Y., & Toettcher, J. E. (2020). Optogenetic

rescue of a patterning mutant. *Current Biology*, 30, 3414-3424.

Johnson, H. E., Goyal, Y., Pannucci, N. L., Schüpbach, T., Shvartsman, S. Y., & Toettcher,

J.E. (2017). The Spatiotemporal Limits of Developmental Erk Signaling. *Developmental Cell*,

40, 185–192.

Kadam, S., McMahon, A., Tzou, P., & Stathopoulos, A. (2009). FGF ligands in Drosophila

have distinct activities required to support cell migration and differentiation. *Development*,

136, 739–747.

Kaur, P., Saunders, T. E., & Tolwinski, N. S. (2017). Coupling optogenetics and light-sheet

microscopy, a method to study Wnt signaling during embryogenesis. *Scientific Reports*, *7*, 1–

11.

Kim, N., Kim, J. M., Lee, M., Kim, C. Y., Chang, K. Y., & Do Heo, W. (2014). Spatiotemporal

control of fibroblast growth factor receptor signals by blue light. *Chemistry & biology*, 21, 903-

912.

Klambt, C., Glazer, L., & Shilo, B. Z. (1992). *breathless*, A Drosophila FGF receptor homolog,

is essential for migration of tracheal and specific midline glial cells. *Genes and Development*,

6, 1668–1678.

Korf-Klingebiel, M., Kempf, T., Schlüter, K. D., Willenbockel, C., Brod, T., Heineke, J., &

Drexler, H. (2011). Conditional transgenic expression of fibroblast growth factor 9 in the adult

mouse heart reduces heart failure mortality after myocardial infarction. Circulation, 123, 504-

514.

Lavoie, H., Gagnon, J., & Therrien, M. (2020). ERK signaling: a master regulator of cell

behaviour, life and fate. *Nature Reviews Molecular Cell Biology*, 21, 607-632.

Li, P., & Elowitz, M. B. (2019). Communication codes in developmental signaling

pathways. *Development*, *146*, dev170977.

Lilly, B., Zhao, B., Ranganayakulu, G., Paterson, B. M., Schulz, R. A., & Olson, E. N. (1995).

Requirement of MADS domain transcription factor D-MEF2 for muscle formation in

Drosophila. *Science*, *267*, 688-693.

Lovato, T., & Cripps, R. (2016). Regulatory Networks that Direct the Development of

Specialized Cell Types in the Drosophila Heart. *Journal of Cardiovascular Development and*

Disease, *3*, 18.

Mandal, L., Dumstrei, K., & Hartenstein, V. (2004). Role of FGFR signaling in the
morphogenesis of the Drosophila visceral musculature. *Developmental dynamics: an official*
publication of the American Association of Anatomists, 231, 342-348.

McMahon, A., Reeves, G. T., Supatto, W., & Stathopoulos, A. (2010). Mesoderm migration in
Drosophila is a multi-step process requiring FGF signaling and integrin activity. *Development*,
137, 2167–2175.

McMahon, A., Supatto, W., Fraser, S. E., & Stathopoulos, A. (2008). Dynamic analyses of
Drosophila gastrulation provide insights into collective cell migration. *Science,* 322, 1546-
1550.

Mele, S., & Johnson, T. K. (2020). Receptor tyrosine kinases in development: Insights from
drosophila. *International Journal of Molecular Sciences*, *21*, 1–21.

Michelson, A. M., Gisselbrecht, S., Buff, E., & Skeath, J. B. (1998). Heartbroken is a specific
downstream mediator of FGF receptor signaling in Drosophila. *Development*, *125*, 4379-4389.

Michelson, A. M., Gisselbrecht, S., Zhou, Y., Baek, K. H., & Buff, E. M. (1998). Dual
functions of the heartless fibroblast growth factor receptor in development of the Drosophila
embryonic mesoderm. *Developmental Genetics*, *22*, 212–229.

Mohammadi, M., Dikic, I., Sorokin, A., Burgess, W. H., Jaye, M., & Schlessinger, J. (1996).
Identification of six novel autophosphorylation sites on fibroblast growth factor receptor 1 and
elucidation of their importance in receptor activation and signal transduction. *Molecular and*
cellular biology, 16, 977-989.

Muha, V., & Müller, H. A. J. (2013). Functions and mechanisms of fibroblast growth factor
(FGF) signaling in Drosophila melanogaster. *International Journal of Molecular Sciences*, *14*,
5920–5937.

Ornitz, D. M., & Itoh, N. (2015). The fibroblast growth factor signaling pathway. *Wiley*
Interdisciplinary Reviews: Developmental Biology, 4, 215-266.

Perrimon, N., Pitsouli, C., & Shilo, B. Z. (2012). Signaling mechanisms controlling cell fate

and embryonic patterning. *Cold Spring Harbor Perspectives in Biology*, 4, a005975.

Presta, M., Chiodelli, P., Giacomini, A., Rusnati, M., & Ronca, R. (2017). Fibroblast growth

factors (FGFs) in cancer: FGF traps as a new therapeutic approach. *Pharmacology &*

therapeutics, *179*, 171-187.

Reichman-Fried, M., & Shilo, B. Z. (1995). Breathless, a Drosophila FGF receptor homolog,

is required for the onset of tracheal cell migration and tracheole formation. *Mechanisms of*

Development, *52*, 265–273.

Reim, I., & Frasch, M. (2010). Genetic and genomic dissection of cardiogenesis in the

Drosophila model. *Pediatric Cardiology*, *31*, 325–334.

Roskoski Jr, R. (2019). Targeting ERK1/2 protein-serine/threonine kinases in human cancers.

Pharmacological research, 142, 151-168.

Sagner, A., & Briscoe, J. (2017). Morphogen interpretation: concentration, time, competence,

and signaling dynamics. *Wiley Interdisciplinary Reviews: Developmental Biology*, *6*, e271.

Schwarz, B., Hollfelder, D., Scharf, K., Hartmann, L., & Reim, I. (2018). Diversification of

heart progenitor cells by EGF signaling and differential modulation of ETS protein activity.

ELife, *7*, 1–36.

Shishido, E., Ono, N., Kojima, T., & Saigo, K. (1997). Requirements of DFR1/Heartless, a

mesoderm-specific Drosophila FGF-receptor, for the formation of heart, visceral and somatic

muscles, and ensheathing of longitudinal axon tracts in CNS. *Development*, *124*, 2119–2128.

Sopko, R., & Perrimon, N. (2013). Receptor tyrosine kinases in Drosophila development. *Cold*

Spring Harbor Perspectives in Biology, *5*, 1–32.

Spivak-Kroizman, T., Lemmon, M. A., Dikic, I., Ladbury, J. E., Pinchasi, D., Huang, J., ... &

Lax, I. (1994). Heparin-induced oligomerization of FGF molecules is responsible for FGF

receptor dimerization, activation, and cell proliferation. *Cell,* 79, 1015-1024.

Stathopoulos, A., Tam, B., Ronshaugen, M., Frasch, M., & Levine, M. (2004). Pyramus and

thisbe: FGF genes that pattern the mesoderm of Drosophila embryos. *Genes and Development*,

18, 687–699.

Teven, C. M., Farina, E. M., Rivas, J., & Reid, R. R. (2014). Fibroblast growth factor (FGF)

signaling in development and skeletal diseases. *Genes and Diseases*, *1*, 199–213.

Thisse, B., & Thisse, C. (2005). Functions and regulations of fibroblast growth factor signaling

during embryonic development. *Developmental Biology*, *287*, 390–402.

Turner, N., & Grose, R. (2010). Fibroblast growth factor signaling: from development to

cancer. *Nature Reviews Cancer*, *10*, 116-129.

Vincent, S., Wilson, R., Coelho, C., Affolter, M., & Leptin, M. (1998). The Drosophila protein

Dof is specifically required for FGF signaling. *Molecular Cell*, *2*, 515–525.

Viswanathan, R., Necakov, A., Trylinski, M., Harish, R. K., Krueger, D., Esposito, E., … De

Renzis, S. (2019). Optogenetic inhibition of Delta reveals digital Notch signaling output during

tissue differentiation. *EMBO Reports*, *20*, e47999.

Vogler, G., & Bodmer, R. (2015). Cellular Mechanisms of Drosophila Heart Morphogenesis.

Journal of Cardiovascular Development and Disease, *2*, 2–16.

Wangler, M. F., Yamamoto, S., & Bellen, H. J. (2015). Fruit flies in biomedical research.

Genetics, 199, 639-653.

Wartlick, O., Mumcu, P., Jülicher, F., & Gonzalez-Gaitan, M. (2011). Understanding

morphogenetic growth control—lessons from flies. *Nature Reviews Molecular Cell Biology*,

12, 594-604.

Wesche, J., Haglund, K., & Haugsten, E. M. (2011). Fibroblast growth factors and their

receptors in cancer. *Biochemical Journal*, *437*, 199-213.

Wilson, R., & Leptin, M. (2000). Fibroblast growth factor receptor-dependent morphogenesis
of the Drosophila mesoderm. *Philosophical Transactions of the Royal Society B: Biological*
Sciences, *355*, 891–895.
719
720 Wilson, R., Vogelsang, E., & Leptin, M. (2005). FGF signaling and the mechanism of
721 mesoderm spreading in Drosophila embryos. *Development*, *132*, 491–501.
722
723 Xie, Y., Su, N., Yang, J., Tan, Q., Huang, S., Jin, M., ... & Chen, H. (2020). FGF/FGFR
724 signaling in health and disease. Signal Transduction and Targeted Therapy, 5, 1-38.
725
726 Yin, J., Lee, R., Ono, Y., Ingham, P. W., & Saunders, T. E. (2018). Spatiotemporal
727 coordination of FGF and Shh signaling underlies the specification of myoblasts in the zebrafish
728 embryo. *Developmental cell*, 46, 735-750.
729
730 Yu, X., Sayegh, R., Maymon, M., Warpeha, K., Klejnot, J., Yang, H., ... & Lin, C. (2009).
731 Formation of nuclear bodies of Arabidopsis CRY2 in response to blue light is associated with
732 its blue light–dependent degradation. *The Plant Cell*, 21, 118-130.
733
734 Zhang, S., Amourda, C., Garfield, D., & Saunders, T. E. (2018). Selective filopodia adhesion
735 ensures robust cell matching in the Drosophila heart. *Developmental Cell*, *46*, 189-203.
736
737 Zhang, S., Teng, X., Toyama, Y., & Saunders, T. E. (2020). Periodic Oscillations of Myosin-
738 II Mechanically Proofread Cell-Cell Connections to Ensure Robust Formation of the Cardiac
739 Vessel. *Current Biology, 70, 3364.*
740
741 Zhou, Y., Popadowski, S. E., Deutschman, E., & Halfon, M. S. (2019). Distinct roles and
742 requirements for Ras pathway signaling in visceral versus somatic muscle founder
743 specification. *Development*, *146*, dev169003.
744
745 Zinner, M., Lukonin, I., & Liberali, P. (2020). Design principles of tissue organisation: How
746 single cells coordinate across scales. *Current Opinion in Cell Biology*, *67*, 37-45.
747
748

Figures:

Fig. 1 Opto-htl expression and activation in different tissues

A) Schematic showing design and activation of Opto-htl. Exposure to 488nm light induces CRY2 clustering leading to activation of the (intracellular) membrane-bound receptor and eventually generating a cellular response via phosphorylation of various downstream target molecules. B) Twi-Gal4>Opto-htl embryos stained with anti-mCherry antibody showing the expression of the construct at various stages. C) Hatchability assay for different genetic conditions. OreR = OregonR, DARK = Twi-Gal4>Opto-htl embryos kept under illumination with amber paper to block 488nm wavelengths throughout development, LIGHT = Twi-Gal4>Opto-htl embryos kept under illumination throughout development. Twi-Gal4 embryos

represent the Gal4 driver alone. UAS-htl-Cry2-mCherry represents Opto-htl embryos with no Gal4 driver. D) Twi-Gal4>Opto-htl embryos fixed and stained at late stage 10/early stage 11 for pErk under dark and light conditions. E) Byn-GAL4>Opto-htl embryos fixed and stained at stage 16 for pErk under dark and light conditions (scale bar 25μm). F) pErk intensity differences in the mesoderm at late stage 10 between Twi-Gal4>Opto-htl embryos kept under dark versus light. G) pErk intensity differences in the hindgut between Byn-GAL4>Opto-htl embryos under dark and light conditions in stage 16 measured in the region shown in (E). Scale bar = 50μm unless stated otherwise. A = Anterior, P = Posterior, D = Dorsal, V = Ventral view. In (F,G), the black bar represents the 95% confidence interval with the Bootstrap distribution shown in orange (see Ho *et al.*, 2019 for details).

Fig. 2 Rescue of *htl* mutant using Opto-htl

A) Comparison between wild-type and *htl* homozygous mutant embryos at different stages: Mesoderm spreading (stage 10), Eve-positive pericardial precursor cells (stage 11) and muscles marked by Myosin staining (stage 15). B) Twi-Gal4>Opto-htl is expressed against *htl* null background and embryos illuminated and stained with Tin antibody. Two homozygous mutants are compared under dark and light conditions for Tin-positive cells. C) Quantification of the number of Tin-positive cells in dark and light conditions for embryos as described in (B). Scale bar = 50μm. A = Anterior, P = Posterior, D = Dorsal, V = Ventral view. In (C), the black bar represents the 95% confidence interval with the Bootstrap distribution shown in orange (see Ho *et al.*, 2019 for details).

Fig. 3 Mesoderm specific defects in Twi-GAL4> UAS - htl-CRY2-mCherry embryos

kept under constant light

(A) Twi-GAL4>Hand::GFP;Opto-htl embryos kept under dark and illuminated conditions, imaged using a light-sheet at stage 15 (Opto-htl signal in magenta). (B) Twi-GAL4>Opto-htl embryos stained with Fas3 and imaged at stage 16 under dark conditions (top) and when illuminated by constant 488nm light (bottom). Svp-positive cells, marked with an asterisk, are identified by lower Fas3 expression. Arrows denote branching of the heart structure. (C) Twi-GAL4>Opto-htl embryos stained with Mef-2 and Eve antibodies at stage 16 under dark and illumination conditions. Arrows correspond to phenotypes described in the text. (D) Muscle structure in Twi-GAL4>Opto-htl embryos kept under dark and light conditions visualised using Opto-htl-mCherry. Scale bar = 50µm unless stated otherwise.

Fig. 4 Spatial control of Opto-htl activation

A) Schematic of the imaging protocol for half-illumination of embryos on a light-sheet microscope. B) Dorsal view of a Twi-Gal4>hand::GFP;Opto-htl embryo illuminated as described in (A) and imaged at stage 16. C) Non-illuminated (top row) and illuminated (bottom row) sides of a Twi-Gal4>hand::GFP;Opto-htl embryo. Left panels, stage 13. Right panels, stage 15/16. VM= Visceral mesoderm, CB= Cardioblasts, PC= Pericardial cells. Scale bar = 50μm.

Fig. 5 Opto-htl induced phenotype depends on light intensity

A) Representative images of the heart at stage 16 in Twi-Gal4>hand::GFP;Opto-htl embryos illuminated from stage 5 till stage 16, at different light intensities. B) Heart at stage 16 in a Twi-Gal4>hand::GFP;Opto-htl embryo kept in the dark through development. C) Survival rate of Twi-Gal4>Opto-htl embryos when illuminated at different intensities throughout development. Scale bar = 50μm.

Fig. 6 Temporal control of Opto-htl activation during development

A) Hatchability assay for Twi-GAL4>Opto-htl embryos illuminated during different time windows during development. (Top) Representative images of the embryo stage being illuminated. (Bottom) Hatching percentage, with the length of each bar representing 100%. B) Hatchability of Twi-GAL4>Opto-htl embryos when illuminated from the specified stage on the x-axis to the end of embryogenesis C) Hatchability of Twi-GAL4>Opto-htl embryos when illuminated from stage 5 until the specified stage on the x-axis (see Table 2A-B for embryo count) D) Twi-GAL4>Opto-htl embryos stained with Fas3, Mef2 and mCherry antibodies under different illumination conditions. Arrowheads point towards Mef-2 marked cardioblasts. Scale bars = 50μm.

Supplementary Fig. 1 Rescue phenotypes using UAS-Opto-htl

A) Mesoderm spreading in heterozygous and homozygous *htl* mutant embryos kept under dark

conditions, imaged at the cross-section (top row) and from the ventral side (bottom row). B)

Mesoderm spreading in heterozygous and homozygous *htl* mutant embryos illuminated from

stage 5 till stage 10. Upon illumination, homozygous mutants expressing Opto-htl exhibit

clustering of mesoderm cells and non-uniform spreading with flattening observed occasionally

in some regions. No rescue of Eve-positive cells is observed in the homozygous mutants under

light either at stage 11 (C) or stage 16 (D). Scale bar = 50μm.

875

876 **Supplementary Fig. 2 Mesodermal cells in Opto-htl embryos**

877 Twi-Gal4>Opto-htl-mCherry embryos fixed and stained at stage 11 with anti-mCherry

878 antibody under dark and light conditions. No expansion of mesodermal cells is observed upon

879 light activation. Scale bar = 50μm unless stated otherwise.

880

881

882 **Supplementary Fig. 3 htl-λ activation in the mesoderm**

883 Dorsal view of Twi-Gal4>UAS-htl-λ embryos fixed and stained at stage 15 with Tin and Eve

884 antibody, compared with WT embryos at the same stage. Asterisks represent ectopic tin cells.

885 Arrowhead point towards eve-positive DA1 muscles and pericardial cells in a given hemi

886 segment. Scale bar = 50μm.

Supplementary Fig. 4 Opto-SOS activation in the mesoderm

Dorsal view of Twi-Gal4>UAS-Opto-SOS embryos fixed and stained at stage 16 with Tin and Eve antibody. Embryos kept under dark show normal heart development with Tin and Eve patterns similar to wild-type. Embryos illuminated at 1mW and 4.5mW light intensity from stage 5 till stage 16 show a progressive increase in both Tin and Eve positive cells with a complete loss of the DA1 muscle group (arrowheads) at 4.5mW intensity. Scale bar = 50μm.

Condition/Genotype	Mef2-CB	Eve-PC	DA1
OreR (n=12)	12	4	2
DARK-twi>Opto-htl (n=10)	12	4	2
Light-twi>Opto-htl (n=10)	29	6	0
	32	7	0
	41	9	0
	26	3	0
	20	6	0
	31	7	0
	30	6	0
	27	7	0
	21	3	0
	23	4	0

Table 1: Number of Mef2-positive cardioblasts, Eve-positive pericardial cells and DA1 muscles in OreR, Twi-Gal4>Opto-htl (dark) and Twi-Gal4>Opto-htl (illuminated) embryos. Cells were counted at stage 15/16 from hemisegments A3-A4.

Illumination onwards stage x till hatching (stage x =)	Illumination time from cellularization stage	Stage Hallmark	No. of embryos screened	No. of embryos hatched	% hatchability
5	0 mins	Cellularisation	31	2	6.4
6/7	40 mins	Gastrulation	7	0	0
8/9	1-2:10 h	Germ band Elongation starts	5	0	0
10	2:10 h	Germ band Elongation finishes	40	1	2.5
12	5:10 h	Germ Band retraction starts	34	0	0
13	7:10 h	Midgut primordium forms a sack	19	17	89
14	8:10 h	Head Involution and DC starts	11	11	100
15	9:10 h	Dorsal Closure	18	18	100
16	11 h	Gut constrictions appear	12	11	91.6
17	14 h	First movements start; Trachea filling	16	16	100

901 **Table 2A:** Hatchability of Twi-GAL4>Opto-htl embryos illuminated from specified stages

902 until end of embryogenesis.

Illumination During stage	Illumination time	No. of embryos screened	No. of embryos hatched	% hatchability
5 till end of stage 7	40 min	7	7	100
5 till end of stg 10	2.5h	7	7	100
5 till end of stg 11	5 h	17	9	52
5 till end of stage 13	8 h	24	0	0

904 **Table 2B:** Hatchability of Twi-GAL4>Opto-htl embryos illuminated during different time

905 windows.

Movie Legends:

Supplementary Movie 1: Opto-htl expression in the mesoderm during embryogenesis
Twi-Gal4>Opto-htl embryo scanned with 561nm laser at 3 min intervals from stage 5 until end of embryogenesis to visualise expression of Opto-htl.

Supplementary Movie 2: Hatchability score for Opto-htl embryos under dark conditions
Twi-Gal4>Opto-htl embryos imaged on a stereoscope covered with amber paper (to block 488nm light) from stage 5 until hatching. (Dark condition).

Supplementary Movie 3: Hatchability score for Opto-htl embryos under constant illumination
Twi-Gal4>Opto-htl embryos imaged on a stereoscope from stage 5 until end of embryogenesis using a 488nm light intensity of 1mW measured at the sample plane. (Light condition).

Supplementary Movie 4: Cardioblast migration and matching in Opto-htl embryo kept under dark conditions
Twi-Gal4>hand::GFP; Opto-htl embryo kept under dark condition until stage 13 and then imaged to visualise the migration of the GFP positive heart cells until matching at stage 16.

Supplementary Movie 5: Cardioblast migration and matching in Opto-htl embryo illuminated with 488nm laser
Twi-Gal4>hand::GFP;Opto-htl embryos illuminated with 488nm laser from late stage 10 until early stage 13 and then imaged using a light-sheet microscope to visualise the migration of the GFP positive heart cells until matching at stage 16. (a) represents dorsal view; (b) and (c) represent lateral views of the same embryo.

933 **Sequences and Primers:**

935 **Myr signal sequence (src42A)**

936
937 ATGGGTAACTGCCTCACCACACAGAAGGGCGAACCCGACAAGCCCGCA
938

940 **Htl FGF cytoplasmic region (Amino acid position 331-729)**
941 (Ref. http://www.uniprot.org/uniprot/Q07407)
942

```
943 TATGCCATCCGAAAGATGAAACATGAAAAGGTGTTGAAACAACGCATCGAAACCGTTCACCAGTGGACCAAGAAAGTGAT
944 CATCTTCAAGCCCGAAGGTGGCGGAGACTCCAGTGGTTCCATGGACACCATGATTATGCCGGTGGTTAGGATACAGAAAC
945 AGCGCACCACTGTTCTTCAGAATGGCAACGAGCCGGCTCCATTCAATGAATATGAATTTCCACTGGACTCGAACTGGGAA
946 CTGCCCAGAAGTCATTTGGTACTGGGTGCCACTTTGGGAGAAGGTGCTTTCGGACGAGTGGTCATGGCGGAGGTCAATAA
947 TGCCATTGTCGCCGTGAAAATGGTGAAGGAAGGACACACGGATGATGACATTGCCAGCTTGGTGCGGGAAATGGAAGTGA
948 TGAAGATCATTGGGCGACATATCAATATTATTAACTTACTTGGTTGCTGCAGTCAAAATGGTCCGCTCTATGTGATTGTC
949 GAGTATGCGCCACACGGAAATCTCAAGGACTTCCTCTATAAAAATCGACCCTTCGGAAGGGATCAGGATAGGGACAGCTC
950 GCAACCGCCGCCATCGCCACCAGCTCATGTGATAACCGAAAAGGATCTGATCAAATTTGCCCACCAAATTGCCAGAGGAA
951 TGGACTATTTGGCCTCGCGGCGATGCATCCATCGAGTTGGCAGCCAGGAATGTGCTCGTCAGCGATGATTATGTGCTG
952 AAGATTGCTGATTTTGGACTGGCGAGGGACATTCAAAGCACGGATTACTATCGGAAGAACACAAATGGCAGGCTACCCAT
953 CAAATGGATGGCACCGGAGTCGCTGCAGGAGAAATTCTATGATTCCAAGACGCGATGTCTGGTCATATGGCATCCTGCTGT
954 GGGAGATCATGACCTATGGGCAGCAACCATATCCAACTATCATGTCCGCTGAGGAGCTGTACACCTATCTCATGTCCGGT
955 CAGCGGATGGAGAAACCAGCGAAATGCTCCATGAACATCTACATTCTGATGCGACAATGTTGGCATTTCAACGCCGACGA
956 TCGGCCACCTTTTACGGAAATTGTTGAGTATATGGACAAGCTGCTCCAGACGAAGGAGGACTACCTCGATGTGGATATCG
957 CCAATCTGGATACACCGCCCTCGACTAGCGACGAGGAGGAAGATGAAACGGACAACCTGCAGAAGTGGTGTAATTAT
958
959
```

960 **CRY2mcherry (Ref. Addgene26866)**

961
```
962 atgaagatggacaaaaagactatagtttggtttagaagagacctaaggattgaggataatcctgcattagcagcagctgc
963 tcacgaaggatctgttttcctgtcttcatttggtgtcctgaagaagaaggacagttttatcctggaagagcttcaagat
964 ggtggatgaaacaatcacttgctcacttatctcaatccttgaaggctcttggatctgacctcactttaatcaaaacccac
965 aacacgatttcagcgatcttggattgtatccgcgttaccggtgctacaaaagtcgtctttaaccacctctatgatcctgt
966 ttcgttagttcgggaccataccgtaaaggagaagctggtggaacgtgggatctctgtgcaaagctacaatggagatctat
967 tgtatgaaccgtgggagatatactgcgaaaagggcaaacctttacgagtttcaattcttactggaagaaatgcttagat
968 atgtcgattgaatccgttatgcttcctcccttggcggttgatgccaataactgcagcggctgaagcgatttgggcgtg
969 ttcgattgaagaactagggctggagaatgaggccgagaaaccgagcaatgcgttgttaactagagcttggtctccaggat
970 ggagcaatgctgataagttactaaatgagttcatcgagaagcagttgatagattatgcaaagaacagcaagaaagttgtt
971 gggaattctacttcactactttctccgtatctccatttcggggaaataagcgtcagacacgttttccagtgtgcccggat
972 gaaacaaattatatgggcaagagataagaacagtgaaggagaagaaagtgcagatctttttcttaggggaatcggtttaa
973 gagagtattctcggtatatatgtttcaacttcccgtttactcacgagcaatcgttgttgagtcatcttcggttttttccct
974 tgggatgctgatgttgataagttcaaggcctggagacaaggcaggaccggttatccgttggtggatgccggaatgagaga
975 gctttgggctaccggatggatgcataacagaataagagtgattgtttcaagctttgctgtgaagtttcttctccttccat
976 ggaaatgggggaatgaagtatttctgggatacacttttggatgctgatttggaatgtgacatccttggctggcagtatatc
977 tctgggagtatccccgatggccacgagcttgatcgcttggacaatcccgcgttacaaggcgccaaatatgacccagaagg
978 tgagtacataaggcaatggcttcccgagcttgcgagattgccaactgaatggatccatcatccatgggacgctcctttaa
979 ccgtactcaaagcttctggtgtggaactcggaacaaactatgcgaaacccattgtagacatcgacacagctcgtgagcta
980 ctagctaaagctatttcaagaacccgtgaagcacagatcatgatcggagcagcaGCCCGGGATCCACCGGTCGCCACCAT
981 GGTGAGCAAGGGCGAGGAGGATAACATGGCCATCATCAAGGAGTTCATGCGCTTCAAGGTGCACATGGAGGGCTCCGTGA
982 ACGGCCACGAGTTCGAGATCGAGGGCGAGGGCGAGGGCCGCCCCTACGAGGGCACCCAGACCGCCAAGCTGAAGGTGACC
983 AAGGGTGGCCCCCTGCCCTTCGCCTGGGACATCCTGTCCCCTCAGTTCATGTACGGCTCCAAGGCCTACGTGAAGCACCC
984 CGCCGACATCCCCGACTACTTGAAGCTGTCCTTCCCCGAGGGCTTCAAGTGGGAGCGCGTGATGAACTTCGAGGACGGCG
985 GCGTGGTGACCGTGACCCAGGACTCCTCCCTGCAGGACGGCGAGTTCATCTACAAGGTGAAGCTGCGCGGCACCAACTTC
986 CCCTCCGACGGCCCCGTAATGCAGAAGAAGACCATGGGCTGGGAGGCCTCCTCCGAGCGGATGTACCCCGAGGACGGCGC
987 CCTGAAGGGCGAGATCAAGCAGAGGCTGAAGCTGAAGGACGGCGGCCACTACGACGCTGAGGTCAAGACCACCTACAAGG
988 CCAAGAAGCCCGTGCAGCTGCCCGGCGCCTACAACGTCAACATCAAGTTGGACATCACCTCCCACAACGAGGACTACACC
989 ATCGTGGAACAGTACGAACGCGCCGAGGGCCGCCACTCCACCGGCGGCATGGACGAGCTGTACAAGTAA
990
991
```

992 **Primers for amplifying FGF cytoplasmic region**

993
994 FP 5'– GAACCCGACAAGCCCGCATATGCCATCCGAAAGATGAAAC –3'

995
996 RP 5'–ctttttgtccatcttcatATAATTACACCACTTCTGCAGGTTGTC–3'

997 **Primers for amplifying CRY2-mcherry**
998
999 FP- 5'-CAGAAGTGGTGTAATTATatgaagatggacaaaaagactatagtttgg-3'
1000
1001 RP 5'- GGGGTGCCTAATGCGGCCGCTTACTTGTACAGCTCGTCCATGC -3'
1002
1003
1004 **Myr sequence synthesized**
1005
1006 5'-GGTATACACCTAGGCGGTACCATGGGTAACTGCCTCACCACACAGAAGGGCGAACCCGACAAGCCCGCATATGCCATCCG
1007 AAAGATG-3'
1008
1009 3'-CCATATGTGGATCCGCCATGGTACCCATTGACGGAGTGGTGTGTCTTCCCGCTTGGGCTGTTCGGGCGTATACGGTAGGC
1010 TTTCTAC-5'